In 3 independent cohorts of young women with SCA, all subjects with DOR were exposed to hydroxyurea
| . | Currently taking hydroxyurea . | “Ever took” hydroxyurea . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | Elchuri18,* . | Hopkinsa . | Hopkinsb . | Multicenter Study of Hydroxyurea5 . | ||||
| Age range, years | 10-21 | 19-30 | 19-30 | 20-30 | ||||
| Median (IQR) | 14.5 (2.5)† | 24 (22, 28) | 24 (22, 28) | 29 (25, 29) | ||||
| . | Currently taking hydroxyurea . | “Ever took” hydroxyurea . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | Elchuri18,* . | Hopkinsa . | Hopkinsb . | Multicenter Study of Hydroxyurea5 . | ||||
| Age range, years | 10-21 | 19-30 | 19-30 | 20-30 | ||||
| Median (IQR) | 14.5 (2.5)† | 24 (22, 28) | 24 (22, 28) | 29 (25, 29) | ||||
| . | HU . | No HU . | HU . | No HU . | Ever HU . | No HU . | Ever HU . | No HU . |
|---|---|---|---|---|---|---|---|---|
| DOR | 8 | 0‡ | 5 | 0‡ | 5 | 0‡ | 14 | 0‡ |
| No DOR | 25 | 14 | 10 | 11 | 19 | 2 | 13 | 2 |
| Risk difference (95% CI) | 0.24 (0.096, 0.39) | 0.33 (0.095, 0.57) | 0.21 (0.046, 0.37) | 0.52 (0.33, 0.71) | ||||
| Number to harm (95% CI) | 4.1 (2.6, 10.4) | 3.0 (1.7, 10.6) | 4.8 (2.7, 21.8) | 1.9 (1.4, 3.0) | ||||
| . | HU . | No HU . | HU . | No HU . | Ever HU . | No HU . | Ever HU . | No HU . |
|---|---|---|---|---|---|---|---|---|
| DOR | 8 | 0‡ | 5 | 0‡ | 5 | 0‡ | 14 | 0‡ |
| No DOR | 25 | 14 | 10 | 11 | 19 | 2 | 13 | 2 |
| Risk difference (95% CI) | 0.24 (0.096, 0.39) | 0.33 (0.095, 0.57) | 0.21 (0.046, 0.37) | 0.52 (0.33, 0.71) | ||||
| Number to harm (95% CI) | 4.1 (2.6, 10.4) | 3.0 (1.7, 10.6) | 4.8 (2.7, 21.8) | 1.9 (1.4, 3.0) | ||||
Elchuri et al described DOR in adolescents with SCA taking hydroxyurea in their study.8 Pecker et al described DOR in adult women with SCA in the Multicenter Study of Hydroxyurea.7 The Multicenter Study of Hydroxyurea dataset precluded the possibility of determining whether hydroxyurea was being used at the time the samples used to measure AMH were procured, but data did identify whoever took hydroxyurea (“Ever took”). We compare subjects, dividing subjects by currently takinga or ever taking (“ever took”) hydroxyureab. No subjects without hydroxyurea exposure had DOR.
Elchuri et al18 measured AMH using Beckman-Coulter AMH Gen II ELISA and defined abnormally low AMH (“DOR”) as <fifth percentile for age. Pecker et al5 measured AMH using Esoterix (LabCorp) assay and defined DOR as AMH <1.1 ng/mL. In this study, we measured Beckman Coulter Access 2 assay and define DOR as AMH <1.1 ng/mL.
Mean values with standard deviation are reported in this publication.
All subjects with DOR had hydroxyurea exposure. Conversely, there was no one without hydroxyurea exposure who had DOR.